IRLAB Therapeutics AB Class A (6IRA) Financial Statements
IRLAB Therapeutics AB Class A Financial Overview
IRLAB Therapeutics AB Class A's market cap is currently $28.23M. The company's EPS TTM is $-0.65; its P/E ratio is -3.21; IRLAB Therapeutics AB Class A has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 57.46M | $ 94.63M | $ 5.68M | $ 61.14M | $ 207.78M |
| Gross Profit | $ -92.35M | $ -92.42M | $ -122.73M | $ -111.23M | $ 168.69M |
| Operating Income | $ -92.35M | $ -75.11M | $ -180.76M | $ -113.11M | $ 52.58M |
| EBITDA | $ -88.03M | $ -68.07M | $ -173.32M | $ -109.13M | $ 56.05M |
| Net Income | $ -110.01M | $ -83.13M | $ -177.84M | $ -114.20M | $ 51.78M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 81.86M | $ 66.92M | $ 111.31M | $ 252.78M | $ 401.90M |
| Total Assets | $ 138.21M | $ 136.21M | $ 177.12M | $ 323.56M | $ 472.45M |
| Total Debt | $ 29.95M | $ 60.42M | $ 27.57M | $ 3.98M | $ 6.60M |
| Net Debt | $ -51.91M | $ -6.50M | $ -83.74M | $ -248.80M | $ -395.30M |
| Total Liabilities | $ 107.49M | $ 103.58M | $ 61.36M | $ 32.72M | $ 72.97M |
| Stockholders' Equity | $ 30.72M | $ 32.63M | $ 115.76M | $ 290.83M | $ 399.48M |
| Cash Flow | |||||
| Free Cash Flow | $ -55.22M | $ -65.79M | $ -165.14M | $ -145.99M | $ 127.93M |
| Operating Cash Flow | $ -55.22M | $ -65.59M | $ -164.85M | $ -142.61M | $ 128.64M |
| Investing Cash Flow | $ 0.00 | $ -199.00K | $ -293.00K | $ -3.38M | $ -708.00K |
| Financing Cash Flow | $ 73.41M | $ 21.40M | $ 23.68M | $ -3.13M | $ -3.04M |
Currency in SEK